Clavis Pharma ASA: Clavis Pharma and Clovis Oncology Extend Partnership and Sign New $205 Million Deal for the Development and Commercialisation of Anti-Cancer Agent CP-4126 in Asia and Rest of the World
New deal expands existing relationship to include global rights to CP-4126
Clavis Pharma to receive up to $205 million in additional staged payments, including a $10 million signing fee, and tiered double-digit royalties on sales
Oslo, Norway, and Boulder, CO, USA. November 11, 2010
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug discovery and development company, and Clovis Oncology, Inc., announced today a new agreement for the further development and commercialisation of CP-4126 (also known as CO-101), which is currently in Phase II development in pancreatic cancer. CP-4126 is a novel, patented, lipid-conjugated form of the anti-cancer drug gemcitabine that has the potential to improve treatment outcomes in a large subset of patients with pancreatic cancer and certain other solid tumours.
Under the terms of the new agreement, Clavis Pharma will receive an upfront cash payment of $10 million from Clovis Oncology for the expansion of the agreement to include global rights and will be eligible to receive further payments totalling $30 million for the successful attainment of development and regulatory milestones in Asia and up to $165 million in sales milestones. This is in addition to the upfront and milestone payments already agreed to in the original license agreement. Clavis Pharma will receive tiered double-digit royalties on all product sales globally.
This new deal expands the existing agreement between Clavis Pharma and Clovis Oncology for the development and commercialisation of CP-4126 in the Americas and Europe, which was signed in November 2009 (up to $380 million in milestone payments plus royalties on sales).
As in the previous agreement, in collaboration with Clavis Pharma, Clovis Oncology will be responsible for the clinical development and registration filings in Asia and the rest of the world. Clavis Pharma will continue to fund some development activities.
Clovis Oncology will now be responsible for the commercialisation of CP-4126 globally, while Clavis Pharma retains an option to co-promote in Europe.
Commenting on the deal, Olav Hellebø, CEO of Clavis Pharma, said:
"We are delighted to be extending our partnership with Clovis Oncology to Asia for the development and commercialisation of our new and improved anti-cancer product CP-4126. For Clavis Pharma, this new agreement represents an important step forward to ensure that CP-4126 will be available to patients globally in the shortest possible time. Clovis Oncology has the requisite expertise in development, regulatory affairs and product commercialisation on a global level to bring CP-4126 to market and we have already established a strong and productive working relationship."
Patrick Mahaffy, President and CEO of Clovis Oncology added:
"We are very pleased to extend our relationship with Clavis to include global rights to CO-101. We have established a strong collaboration with Clavis and believe this allows us to develop the drug consistently in Japan, China, and additional Asian and international markets. We are already planning the development of our preclinical lung cancer compound in Asia so this expansion of our agreement with Clavis is also highly complementary to our global development and commercialisation strategy."
About CP-4126 (also known as CO-101) and Pancreatic Cancer
CP-4126 is a novel, patented, lipid-conjugated derivative of the anti-cancer drug gemcitabine, developed using Clavis' lipid vector technology (LVT). It is designed to improve upon the efficacy of gemcitabine by enabling the drug to enter cancer cells without requiring the presence of transporter proteins. The entry of gemcitabine into tumour cells has been shown to be dependent upon the expression of specific membrane transporter proteins, particularly hENT1 (human equilibrative nucleoside transporter 1). Gemcitabine is the current standard treatment for advanced pancreatic cancer, and is also used in combination with other chemotherapy agents for the treatment of other cancers, including non-small cell lung, ovarian, gastro-intestinal and breast cancer.
It is estimated that due to deficient expression of the transport protein, hENT1, at least 50% of patients with pancreatic tumours have limited cellular uptake of gemcitabine and therefore respond poorly to treatment. This has been confirmed in several studies of patients with pancreatic cancer where a low level of the hENT1 biomarker has been correlated with poor outcomes after gemcitabine therapy and high levels of hENT1 correlated with significant better survival outcomes. Published research has also suggested that hENT1 levels correlate with outcomes in lung cancer patients treated with gemcitabine-containing chemotherapy. Due to its different molecular design, CP-4126 is absorbed by cancer cells independent of hENT1 levels, which may lead to an improvement in efficacy in the poorly-served group of hENT1-low patients.
Pancreatic cancer presents a major unmet medical need due to the poor survival outcomes and limited number of therapeutic options available to patients. Approximately 43,000 new cases of pancreatic cancer will occur in the US in 2010, with a similar number occurring in Europe. The 1-year and 5-year overall survival rates are estimated at 23% and 4%, respectively. The majority of pancreatic cancer patients are diagnosed with unresectable locally advanced or metastatic disease. Median overall survival in these advanced patients is 4-10 months. CP-4126 has been granted orphan drug designations for the treatment of pancreatic cancer in the US and EU.
Clinical Development of CP-4126
Following the phase I study performed by Clavis Pharma, Clovis Oncology initiated an international, randomised, Phase II trial of CP-4126 versus gemcitabine in mid-2010, with overall survival as a primary endpoint. The trial is progressing as planned with clinical sites opening and patient enrolment ongoing in Europe, the US, South America and Australia. Results of this trial are anticipated in 2012. While the trial is evaluating CP-4126 in patients who express either high or low levels of the hENT1 biomarker, the primary analysis will be overall survival in the hENT1-low population. If successful, Clovis Oncology anticipates filing for marketing approval in the United States and in the EU by year end 2012.
A new clinical trial with CP-4126 in second-line pancreatic cancer patients will be initiated by the end of this year, and a retrospective observational study to define the criteria for determining low/high hENT1 expression levels will begin shortly as well.
Clovis Oncology has signed an agreement with Ventana Medical Inc., a subsidiary of Roche, to develop and commercialise the novel hENT1 biomarker diagnostic method as a companion diagnostic for CP-4126.
For Further Information Contact:
For Clavis Pharma|
Chief Executive Officer
+47 24 11 09 50
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
For Clovis Oncology |
Anna Sussman / Breanna Burkart
Scout Investor Relations
+1 303 907 5358 or +1 303 907 5162
firstname.lastname@example.org or email@example.com
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The Company is currently developing CO-101 which is in Phase 2 development for the treatment of pancreatic cancer. The Company is collaborating with Ventana Medical Systems to develop a hENT1 assay to identify patients likely to benefit from CO-101. The Company is also developing an epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) which is currently in pre-clinical development for non-small cell lung cancer (NSCLC) patients who express the T790M mutation along with a companion diagnostic to identify patients with the T790M mutation.
The Company is headquartered in Boulder, Colorado, and has additional offices in San Francisco and Cambridge, England.
For more information about Clovis Oncology, please visit the Company's website at www.clovisoncology.com
About Clavis Pharma
Clavis Pharma ASA is a clinical stage oncology discovery and drug development company based in Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration, altered metabolism and, in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
- Elacytarabine, a leukaemia drug, currently in a randomized, controlled Phase III study in late-stage acute myeloid leukaemia;
- CP-4126, is currently in a Phase II comparative study with gemcitabine for the treatment of pancreatic cancer;
- CP-4200, an azacitidine derivative, in preclinical development for myelodysplastic syndrome (MDS), a disease that is often a precursor to leukaemia.
Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. CP-4126 is licensed to Clovis Oncology globally. Clavis Pharma has an option to co-promote CP-4126 in Europe.
The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.
This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Clavis Pharma. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.
No expressed or implied representations or warranties are given concerning Clavis Pharma or the accuracy or completeness of the information or projections provided herein, and no claims shall be made by the recipient hereof by virtue of this Information Memorandum or the information or projections contained herein. Any representations or warranties made to an investor in Clavis Pharma will be subject to separate sale and purchase agreements to be negotiated between the parties. Clavis Pharma is a registered trademark of Clavis Pharma ASA.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Clavis Pharma ASA via Thomson Reuters ONE
- Pope attacks mega-salaries and wealth gap in peace message
- Air strike kills 15 civilians in Yemen by mistake: officials
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
- South Africa admits error over 'schizophrenic' Mandela signer |